Study of ALXN1830 Administered Subcutaneously in Adults With Generalized

Clinical Trial Description

Participants have the option to enroll in an Open-label Extension (OLE) Period to receive ALXN1830 up to 58 weeks (including follow-up period). ;

Study Design

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05514873` - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors	Phase 3
Completed	`NCT04124965` - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT04833894` - Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	Phase 2/Phase 3
Active, not recruiting	`NCT04963270` - A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis	Phase 3
Active, not recruiting	`NCT02950155` - A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis	Phase 3
Completed	`NCT03315130` - Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis	Phase 2
Recruiting	`NCT05556096` - Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Phase 3
Not yet recruiting	`NCT06392386` - A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis	Phase 3
Not yet recruiting	`NCT06149559` - A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis	Phase 2/Phase 3
Not yet recruiting	`NCT06193889` - A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT03920293` - Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis	Phase 3
Completed	`NCT03770403` - A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.	Phase 3
Not yet recruiting	`NCT06447597` - A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.	Phase 2/Phase 3
Completed	`NCT03971422` - A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT05403541` - Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis	Phase 3
Recruiting	`NCT05644561` - Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)	Phase 3
Not yet recruiting	`NCT06456580` - A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)	Phase 3
Not yet recruiting	`NCT06463587` - Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)	Phase 3
Recruiting	`NCT06055959` - A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis	Phase 2/Phase 3
Completed	`NCT00515450` - Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis	Phase 3

NCT number	NCT04982289
Study type	Interventional
Source	Alexion Pharmaceuticals
Contact
Status	Withdrawn
Phase	Phase 2
Start date	January 1, 2022
Completion date	January 31, 2024

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms